"When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that."
Co-chair and Trustee, Bill & Melinda Gates Foundation
"The Access to Medicine Index is a very important project. What gets measured, gets done."
Dr. Margaret Chan
Former Director General, World Health Organisation
"This independent Antimicrobial Resistance Benchmark is a huge step forward and shines a light on the pharmaceutical industry’s progress in tackling drug-resistant infections. It can help pave the way for a transparent learning culture where best practice is shared, progress celebrated, and gaps where further work is needed are identified.”
Dame Sally Davies
Professor Dame Sally Davies, Chief Medical Officer and co-convener of the UN Inter-Agency Co-ordination Group on AMR
"You should be commended for taking on this difficult task in the environment of a consolidated industry with many atypical manufacturers playing important roles. We feel that the ATVI has struck a good balance, recognizing the elements that are important in access to vaccines, taking a systematic approach to comparing across manufacturers, yet recognizing and appreciating the differences in this industry."
Dr. Seth Berkley
CEO, the GAVI Alliance
“The pharmaceutical industry’s role in tackling drug-resistant infections extends beyond developing new treatments. The AMR Benchmark makes clear where companies are making commendable efforts to tackle this urgent global health problem – and it shows where further effort must now be focused. Wellcome is committed to working with industry and governments to answer the questions this report raises, by supporting new product development, and helping ensure antibiotics, old and new, are used appropriately and are available to all patients who need them.”
Director of the Wellcome Trust
“The AMR Benchmark is the first independent initiative that evaluates what pharmaceutical companies are doing to address AMR. It is clearly encouraging to see some actions to reduce the environmental pollution of antibiotics from manufacturing. However, there is still much room for improvement, particularly with regards to transparency. Incentives from outside, like the AMR Benchmark, are critically important to make sure that the pharmaceutical industry keeps moving forward.”
Prof. Joakim Larsson, Director, Centre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Sweden
"We desperately need new antibiotics, but we can’t let the new ones go to waste. The AMR Benchmark is an important tool to spur progress on innovation, appropriate use, and clean manufacturing, providing an independent assessment following the Davos Declaration and the Industry Roadmap released in 2016."
Professor of Law at Boston University and Executive Director of CARB-X
"I’ve been impressed by the Access to Medicine Index. It presents well-balanced stakeholder views on good practices for the pharmaceutical industry and it provides clear standards against which the performance of individual companies can be judged."
President, Realizing Rights, Former UN High Commissioner for Human Rights (1997-2002), Former President of Ireland (1990-1997)
"The Access to Medicine Index mobilises the strength of the private sector, impacting the lives of millions of the most vulnerable people on earth. It showcases the synergy of aid, trade and investment."
Former Minister for Foreign Trade and Development Cooperation
"There is more that we can do and are doing. This year, the index is tougher than ever. It challenges us to think harder about how we drive innovation and enable access to our products. This is a challenge that we are ready and willing to take on. We will continue to push ourselves to go further and faster to make sure our medicines and vaccines reach more people."
Sir Andrew Witty
Former CEO, GlaxoSmithKline plc
"Accountability is indispensable to the full implementation of the right to health, and the Access to Medicine Index plays an important role in promoting the responsibility of pharmaceutical corporations for a core element of the right to health – the right of everyone to access essential medicines."
Zeid Ra'ad Al Hussein
Former High Commissioner for Human Rights, United Nations
"But we at Novartis are only one piece of the puzzle. Tools like the Access to Medicine Index are useful in encouraging the pharmaceuticals industry to improve access."
Former CEO, Novartis AG
"This year’s index shows that the pharmaceutical industry has made progress in improving access to vital medicines for the globe’s poorest people, helping to tackle some of the world’s worst diseases. The deadly Ebola outbreak reminds us that there is still much to be done to stop the spread of diseases in developing countries."
The Rt Hon. Justine Greening
MP, Former Secretary of State for International Development,UK
"Licensing agreements between pharmaceutical companies and the Medicines Patent Pool can benefit 87-94% of people living with HIV in the developing world, and produce up to USD1.4 billion of savings for the international community. The Access to Medicine Foundation incentivises companies to engage with us and is one of our key partners to achieve impact."
Assistant Director General, IFPMA
"The work of the Access to Medicine Foundation is powerful because it shows how pharmaceutical companies can and should integrate access to medicine into their business strategies. This empowers local civil society organisations to advocate for more sustainable initiatives."
Executive Director AIDS Accountability, Pan African Civil Society Platform on Access to Medicines
"The Sustainable Development Goals and human rights demand accountability, which consists of monitoring, review and remedial action. By deepening monitoring, the Access to Medicine Foundation makes an indispensable contribution towards the accountability of pharmaceutical companies for the SDGs."
Professor of Law at Essex University, former UN Special Rapporteur on the right to health
"It is crucial for a CEO to have a dialogue with his/her company’s stakeholders. The Access to Medicine Index stimulates this dialogue, which is essential to bring all parties together. For this reason I highly recommend other sectors use this model as well."
Chair Supervisory Board, STOP AIDS NOW, Former CEO of Heineken (1993-2006)
"The Access to Medicine Index has proven to provide much-needed transparency into pharmaceutical industry actions and policies. That will ultimately lead to greater access to healthcare for millions of people all over the globe."
Former Executive Director, World Bank (2006-2008), Former Chair of Rabobank (1999-2006)
"Companies are beginning to understand that the value of corporate social responsibility programmes is not only the opportunity to do the right thing but that it's good for business as well. The Access to Medicine Index provides companies with a chance to improve performance and explore new business models while helping societies in need."
Former CEO of RiskMetrics Group, Former CEO of Norges Bank Investment Management (NBIM)
"The AMR Benchmark brings much-needed clarity to how pharmaceutical companies approach AMR, which means investors can assess how pharmaceutical companies manage opportunities and risks created by drug-resistant infections. Such scrutiny by investors will spur pharma executives to greater activity."
Former Chair of the UK Review on AMR
“The Sustainable Development Goals will only be achieved through close collaboration between the public and private sectors. Independent, data-driven benchmarks are essential to tracking and assessing progress against the world’s biggest challenges. This new Antimicrobial Resistance Benchmark will enable business, government, and civil society to work together to create a healthier, safer world against the emerging global threat posed by superbugs.”
President and Chief Executive Officer of the United Nations Foundation.
“Without the cooperation and consensus of the biggest pharmaceutical companies and all of their stakeholders, it is impossible to address today’s global health challenges. There are still so many people worldwide who cannot access the medicine they need. At the same time, I see that the will from all stakeholders to reach them is rapidly growing.”
Founder of the Access to Medicine Foundation.
“I welcome this comprehensive article on ending the burden of HIV, malaria and TB in children, and especially appreciate the strong emphasis on the crying need for children living with HIV to access the most up-to-date paediatric ARVs.”
Sister Mary Owens
Executive Director of COGRI - Nyumbani programs for children living with HIV
"I support the Access to Medicine Foundation's work to draw attention to the pressing issue of paediatric drug resistance and specifically pertaining to HIV, malaria and TB, along with their work to incentivise pharmaceutical companies to do more for children living in low-and-middle-income countries. Going forward, the need for new vaccines and treatments for children to address ongoing epidemics must not be forgotten.''
Professor Mike Sharland
Consultant in Paediatric Infectious Diseases at St George's University Hospitals NHS Foundation Trust
"No child should die of TB. That is why we’re working with our partners to expand the pediatric R&D pipeline. We welcome this new report for highlighting the progress to date and raising awareness of the work that still needs to be done to advance the development and delivery of new child-friendly MDR-TB treatments.”
President and CEO, TB Alliance
"While COVID19 is dominating health systems globally, many children are still on the frontlines of the ‘big three’ infectious diseases — HIV, malaria and TB — all of which still require urgent vaccine development to save lives. The Access to Medicine Foundation provides important research and analysis on key paediatric access and drug resistance issues and incentivises companies to take action.''
Ambassador for Women's Rights and Gender Equality, Dutch Ministry of Foreign Affairs
View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.